查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1988494

CD抗原癌症治疗市场：依治疗方法、癌症类型和标靶划分－2026-2032年全球预测

CD Antigen Cancer Therapy Market by Therapy Type, Cancer Type, Targeted - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

CD抗原癌症治疗市场预计到2025年将达到118.1亿美元，到2026年将成长到125.9亿美元，到2032年将达到192.2亿美元，复合年增长率为7.19%。

主要市场统计数据
基准年 2025 118.1亿美元
预计年份：2026年 125.9亿美元
预测年份 2032 192.2亿美元
复合年增长率 (%) 7.19%

对 CD 抗原标靶肿瘤治疗方法进行权威概述，整合科学证据、临床趋势和商业化影响，供决策者参考。

以CD抗原为标靶的癌症治疗融合了分子生物学、免疫工程和精准递送技术，催生了新的治疗方法。过去十年，转化研究逐步揭示了哪些CD表面标誌物可用于选择性区分恶性组织和正常组织，从而能够设计出基于抗体的偶联物、基因修饰细胞疗法以及优化的生物製药，在确保疗效的同时控制毒性。

工程、监管和製造领域的整合创新如何重新定义 CD 抗原靶向肿瘤干预的路径和商业性动态。

针对艰难梭菌抗原的癌症治疗格局正在经历一场变革，这主要得益于技术和製度层面的共同推动。标靶化载荷工程和连接子化学的进步提高了抗体药物复合体的治疗指数，从而增强了肿瘤选择性并降低了脱靶效应。同时，新一代CAR-T细胞构建体融合了逻辑门控、强化细胞激素表达和关闭机制，将细胞疗法的应用范围从血液系统恶性肿瘤扩展到特定的固态肿瘤微环境。

我们将评估关税政策的变化如何重塑艰难梭菌抗原癌症疗法整个价值链的采购、製造地和业务永续营运。

预计2025年美国关税政策的转变将对CD抗原癌症疗法相关的整个采购、生产和临床供应链产生累积。进口试剂、一次性塑胶製品、特殊过滤膜和某些实验室设备的关税可能会逐步增加生物製药生产和临床试验所需关键材料的接收成本。因此，各机构在早期专案中可能会面临营运利润率下降的压力，以及处理测试样本和生物製程耗材的可变成本增加。

基于细分的洞察揭示了治疗方法和癌症适应症的组合如何决定开发复杂性、监管方法和商业化途径。

细分市场分析揭示了每种治疗方法和疾病适应症在研发路径和策略重点上的显着差异，这影响着临床试验设计、生产复杂性和商业化策略。根据治疗方法类型，本研究对抗体药物复合体(ADC)、嵌合体抗原受体 (CAR) T 细胞治疗方法以及传统生物製药作用机制的整个过程。每种治疗方法都有其独特的需求。抗体药物复合体(ADC) 需要先进的连接子和有效载荷优化，以及对肿瘤浸润的可靠评估。 CAR T 细胞疗法需要患者特异性细胞采集、体外操作和长期安全性监测。单株抗体则依赖成熟的生物製药生产技术和大规模分销管道。

区域管理体制、临床生态系统和製造地如何影响全球差异化的研发和打入市场策略？

区域趋势对艰难梭菌抗原疗法的研发、取得和推广轨迹有显着影响，各主要区域的法规环境、临床试验系统和支付方考量各不相同。在美洲，大规模的临床试验能力、集中化的监管审查体係以及高度集中的专业治疗中心正在加速一线人体试验的启动和商业化进程，同时，也需要强有力的证据支持来应对支付方的审查。欧洲、中东和非洲（EMEA）的情况则较为复杂，集中式和国家监管要求并存，报销途径因市场而异，区域製造地在确保供应连续性和市场准入方面发挥战略作用。亚太地区的特点是研发能力快速提升、国内生物技术生态系统不断发展，以及法规结构日趋完善，越来越支持快速审批和本地化生产伙伴关係，因此，对于许多申办方而言，亚太地区在生产和患者招募方面都是高度优先考虑的区域。

本书揭示了决定 CD 抗原肿瘤学竞争地位的企业级策略模式，包括如何确定伙伴关係、平台深度和生产规模。

CD抗原疗法领域主要企业之间的竞争格局反映了平台专业化、策略联盟和生产能力发展三者之间的相互作用。成熟的製药公司越来越多地与高度专业化的创新企业合作或进行收购，以获取尖端有效载荷、细胞工程平台和互补的诊断技术。这些合作关係通常包括共同投资扩大生产规模、共同开发契约的适应症以及平衡风险和潜在收益的许可模式。

为协调科学检验、生产灵活性和证据生成，以从艰难梭菌抗原疗法中提取可持续的商业性价值，提供实用的策略指南。

产业领导企业应采取整合策略，将科学重点与业务和商业性执行结合，以最大限度地发挥CD抗原标靶治疗的潜力。首先，在研发早期阶段优先考虑标靶检验和病患选择策略，以降低后期临床试验成本高昂的风险，并增强对支付方和合作伙伴的价值提案。其次，透过将内部生产能力与成熟的契约製造合作伙伴结合，投资于生产柔软性，以平衡规模、速度和品质保证，同时规避供应链中断风险。

透明且可重复的混合方法，结合专家访谈、文献整合和迭代检验，为严谨的市场洞察奠定了基础。

本分析的调查方法融合了第一手资料和第二手资料，以确保研究的严谨性、多方验证性以及对决策者的相关性。第一手资料包括对行业高管、临床研究人员、生产专家和支付方进行结构化访谈，以了解他们对研发瓶颈、营运限制和商业性优先事项的真实观点。第二手资料则整合了同行评审文献、监管指导文件、临床试验註册数据和企业资讯披露，以梳理技术趋势、临床进展和监管先例。

整合 CD 抗原疗法的科学潜力和实际应用，并制定策略重点，将创新转化为可及的癌症治疗。

总之，针对艰难梭菌抗原的癌症治疗方法处于肿瘤学创新战略前沿，科学进步、生产技术革新和监管调整在此交汇融合，创造了意义重大的临床机会。治疗方法的固有复杂性与适应症带来的临床挑战之间的相互作用，凸显了製定个体化优化开发策略的必要性，这些策略需要在技术差异化和切实可行的营运计划之间取得平衡。此外，贸易政策和区域监管差异等外部因素也会带来结构性问题，这些问题会影响采购、生产在地化和实证策略。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：CD抗原癌症治疗市场（依治疗方法划分）

  • 抗体药物复合体
  • 嵌合体抗原受体（CAR）T细胞疗法
  • 单株抗体

第九章：CD抗原癌症治疗市场（依癌症类型划分）

  • 骨髓恶性肿瘤
  • 固态肿瘤

第十章：Target 公司的 CD 抗原癌症治疗市场

  • CD19
  • CD20
  • CD30
  • CD33
  • CD38
  • CD70

第十一章：CD抗原癌症治疗市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章：CD抗原癌症治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章：CD抗原癌症治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章：美国艰难梭菌抗原癌症治疗市场

第十五章：中国大肠桿菌抗原癌症治疗市场

第十六章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • Exelixis, Inc.
  • Genmab A/S
  • Gilead Sciences, Inc.
  • Illumina, Inc.
  • Incyte Corporation
  • Jazz Pharmaceuticals PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi SA
  • Seagen Inc.
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-9A2BA9536662

The CD Antigen Cancer Therapy Market was valued at USD 11.81 billion in 2025 and is projected to grow to USD 12.59 billion in 2026, with a CAGR of 7.19%, reaching USD 19.22 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 11.81 billion
Estimated Year [2026] USD 12.59 billion
Forecast Year [2032] USD 19.22 billion
CAGR (%) 7.19%

An authoritative overview of CD antigen-directed oncology approaches that synthesizes scientific rationale, clinical momentum, and commercialization implications for decision-makers

CD antigen-targeted cancer therapies represent a convergent space where molecular biology, immune engineering, and precision delivery technologies intersect to create new modalities of care. Over the past decade, translational research has progressively clarified which cluster of CD surface markers can be selectively exploited to distinguish malignant from healthy tissue, enabling the design of antibody-based conjugates, engineered cellular therapies, and optimized biologics that deliver efficacy while managing toxicity.

Clinical validation of multiple CD targets in hematological malignancies has catalyzed interest in expanding those approaches into solid tumors, where tumor microenvironment heterogeneity and antigen expression variability create additional complexities. Concurrently, manufacturing advances and regulatory adaptations have reduced development timelines for complex biologics, increasing the number of assets advancing into late-stage development. These shifts have broadened the stakeholder base to include not only specialized biotech innovators but also established pharmaceutical companies, contract manufacturing organizations, and specialized service providers.

Taken together, these dynamics position CD antigen-targeted approaches as a strategic priority for organizations pursuing durable, targeted oncology solutions. As a result, careful attention to translational science, clinical design, supply chain resilience, and payer engagement will be required to convert scientific promise into sustainable clinical and commercial impact.

How convergent innovations in engineering, regulation, and manufacturing are redefining the trajectory and commercial dynamics of CD antigen-targeted oncology interventions

The landscape for CD antigen cancer therapies is undergoing transformative shifts driven by convergent technological and systemic forces. Advances in targeted payload engineering and linker chemistry have enhanced the therapeutic index of antibody-drug conjugates, enabling higher tumor selectivity and reduced off-target effects. At the same time, next-generation CAR T-cell constructs that incorporate logic gating, armored cytokine expression, and off-switch mechanisms are extending the feasibility of cellular therapies beyond blood cancers and into certain solid tumor niches.

Parallel to scientific progress, regulatory frameworks are evolving to accommodate complex biologics, with agencies increasingly receptive to adaptive trial designs and real-world evidence to inform approval pathways. Manufacturing innovations such as decentralized production models, automation, and digital batch tracking are redefining scalability and quality control practices, thereby lowering operational friction for high-complexity therapies. In commercial terms, stakeholder expectations are shifting toward integrated care solutions that bundle diagnostics, access support, and long-term patient monitoring.

Consequently, organizations that align R&D priorities with flexible manufacturing, robust evidence generation, and collaborative payer strategies will be best positioned to capture opportunity in a landscape that rewards technical differentiation and patient-centered delivery models.

Assessing how tariff policy changes are reshaping sourcing, manufacturing footprints, and operational resilience across the CD antigen oncology value chain

The cumulative impact of tariff policy shifts in the United States in 2025 is expected to reverberate across procurement, manufacturing, and clinical supply networks involved in CD antigen cancer therapies. Tariffs on imported reagents, single-use plastics, specialized filtration membranes, and certain laboratory instruments can incrementally raise the landed cost of critical inputs required for biologics production and clinical trial execution. As a consequence, organizations may experience compressed operating margins on early-stage programs and face higher variable costs for trial sample handling and bioprocessing consumables.

Moreover, tariff-driven cost pressures can influence strategic sourcing decisions, prompting greater localization of supply chains and renewed investment in domestic manufacturing capacity. This pivot may improve supply reliability over time but often requires upfront capital expenditures and workforce development to shore up capabilities in sterility assurance, aseptic fill-finish, and cold chain logistics. In parallel, smaller developers and academic sponsors that lack integrated manufacturing may face amplified operational challenges, increasing the importance of contract manufacturing partnerships and collaborative procurement models.

In sum, tariff dynamics function as a structural variable that can reshape vendor selection, manufacturing footprints, and cost management strategies. Proactive scenario planning and strategic supplier engagement are therefore essential to mitigate short-term disruptions while capturing the long-term benefits of a more resilient and geographically diversified production ecosystem.

Critical segmentation-driven insights demonstrating how therapy modality and cancer indication jointly dictate development complexity, regulatory approach, and commercialization pathways

Segmentation analysis reveals meaningful differences in development pathways and strategic focus across modality and disease indications, with implications for clinical design, manufacturing complexity, and commercialization approaches. Based on Therapy Type, market is studied across Antibody-Drug Conjugates, Chimeric Antigen Receptor (CAR) T-cell Therapy, and Monoclonal Antibodies, which collectively span a continuum from targeted payload delivery to living cell modalities and classic biologic mechanisms. Each therapy type presents distinct requirements: antibody-drug conjugates necessitate advanced linker and payload optimization and robust tumor penetration assessments; CAR T-cell programs demand individualized cell collection, ex vivo manipulation, and long-term safety monitoring; monoclonal antibodies rely on well-established biologics manufacturing and large-scale distribution channels.

Based on Cancer Type, market is studied across Hematological Malignancies and Solid Tumors, categories that diverge in antigen accessibility, microenvironmental hurdles, and clinical endpoint expectations. Hematological malignancies often provide more uniform antigen expression and established response criteria, enabling faster proof-of-concept studies, whereas solid tumors require strategies to address antigen heterogeneity, stromal barriers, and intratumoral delivery. Together, these intersecting segmentation dimensions inform priorities for target selection, trial site networks, companion diagnostic needs, and post-market surveillance strategies. Accordingly, sponsors should tailor development plans to the modality-specific manufacturing pathways and the clinical complexities associated with the targeted cancer type.

How regional regulatory regimes, clinical ecosystems, and manufacturing footprints shape differentiated development and market entry strategies across global regions

Regional dynamics materially influence development, access, and adoption trajectories for CD antigen therapies, with differentiated regulatory environments, clinical trial ecosystems, and payer considerations across major geographies. In the Americas, sizable clinical trial capacity, centralized regulatory review structures, and a high concentration of specialized treatment centers accelerate first-in-human studies and commercial launches, while also necessitating robust evidence packages that address payer scrutiny. Europe, Middle East & Africa present a heterogeneous landscape where centralized and national regulatory requirements coexist, reimbursement pathways vary significantly by market, and regional manufacturing hubs can play a strategic role in addressing supply continuity and market access timelines. Asia-Pacific features rapidly expanding research capacity, growing domestic biotech ecosystems, and evolving regulatory frameworks that increasingly support expedited reviews and localized manufacturing partnerships, making the region both a production and patient recruitment priority for many sponsors.

These regional characteristics affect strategic choices about trial site selection, regulatory filings, and commercial deployment. Sponsors should consider leveraging regional centers of excellence for complex therapy delivery, aligning evidence generation with diverse payer expectations, and planning manufacturing footprints that reduce logistical risk while optimizing time to patient.

Strategic company-level patterns that reveal how partnerships, platform depth, and manufacturing scale determine competitive positioning in CD antigen oncology

Competitive dynamics among leading companies in the CD antigen therapy arena reflect a mix of platform specialization, strategic collaborations, and manufacturing capability development. Established pharmaceutical companies are increasingly partnering with or acquiring specialized innovators to access cutting-edge payloads, cell engineering platforms, and diagnostic complements. These collaborations often include shared investments in manufacturing scale-up, co-development agreements to expand indications, and licensing models that balance risk with potential upside.

Smaller biotechs and cell therapy pioneers continue to drive scientific differentiation through novel antigen targeting, multi-specific constructs, and improved safety switches for cellular products. At the same time, specialized contract service providers and manufacturing partners have expanded capacity and expertise to support complex biologics and autologous therapy workflows, offering modular solutions that allow sponsors to accelerate timelines without fully internalizing capital-intensive production. Overall, successful organizations demonstrate a blend of technological depth, robust clinical development strategies, and an operational focus on quality systems, regulatory readiness, and supply chain resilience that together enable sustained advancement from R&D through commercialization.

Actionable strategic directives that align scientific validation, manufacturing agility, and evidence generation to unlock durable commercial value from CD antigen therapies

Industry leaders should adopt an integrated strategy that aligns scientific prioritization with operational and commercial execution to maximize the potential of CD antigen-targeted therapies. First, prioritize target validation and patient selection strategies early in development to de-risk expensive late-stage studies and to strengthen the value proposition for payers and partners. Second, invest in manufacturing flexibility by combining internal capabilities with validated contract manufacturing partners to balance scale, speed, and quality assurance while hedging against supply chain disruptions.

Third, design evidence-generation plans that incorporate prospective real-world data collection and adaptive trial elements to support regulatory dialogue and payer negotiations. Fourth, pursue strategic partnerships that couple complementary platforms-such as combining antibody-drug conjugate expertise with novel payload chemistry or pairing cell therapy engineering with scalable manufacturing platforms-to accelerate time to proof-of-concept. Finally, build multidisciplinary commercialization playbooks that include diagnostic alignment, long-term safety monitoring plans, and patient support services to facilitate adoption and reimbursement. By executing on these pragmatic, coordinated actions, companies can convert technological promise into durable clinical and commercial outcomes.

A transparent and reproducible mixed-methods approach combining expert interviews, literature synthesis, and iterative validation to underpin rigorous market insights

The research methodology underpinning this analysis integrates primary and secondary approaches to ensure rigor, triangulation, and relevance to decision-makers. Primary research included structured interviews with industry executives, clinical investigators, manufacturing experts, and payers to capture real-world perspectives on development bottlenecks, operational constraints, and commercial priorities. Secondary research synthesized peer-reviewed literature, regulatory guidance documents, clinical trial registries, and company disclosures to map technological trends, clinical progress, and regulatory precedent.

Data synthesis employed cross-validation techniques and expert panels to reconcile divergent views and to test scenario assumptions. The methodology emphasized transparency in source attribution, iterative expert review cycles, and sensitivity checks to highlight areas of consensus and uncertainty. Limitations include rapidly evolving clinical data streams and region-specific regulatory changes that may alter the competitive landscape; consequently, the analysis is designed to be operationalized through periodic updates, targeted follow-up interviews, and tailored workshops that extend the core findings into bespoke strategic plans.

A synthesis that distills the scientific promise and operational realities of CD antigen therapies into strategic priorities for translating innovation into accessible oncology care

In conclusion, CD antigen-targeted cancer therapies occupy a strategic frontier of oncology innovation where scientific advances, manufacturing evolution, and regulatory adaptation converge to create meaningful clinical opportunities. The interplay between modality-specific complexities and indication-driven clinical challenges underscores the need for tailored development strategies that balance technical differentiation with pragmatic operational planning. Moreover, external factors such as trade policy and regional regulatory divergence introduce structural considerations that can influence sourcing, manufacturing localization, and evidence strategies.

Organizations that integrate robust target validation, flexible manufacturing partnerships, and proactive payer-engagement plans will be well-positioned to navigate the emerging landscape. Ultimately, success in this domain requires a systems-level perspective that aligns translational science, clinical design, and commercial execution to deliver therapies that are not only effective but also accessible and sustainable for patients and health systems alike.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. CD Antigen Cancer Therapy Market, by Therapy Type

  • 8.1. Antibody-Drug Conjugates
  • 8.2. Chimeric Antigen Receptor (CAR) T-cell Therapy
  • 8.3. Monoclonal Antibodies

9. CD Antigen Cancer Therapy Market, by Cancer Type

  • 9.1. Hematological Malignancies
  • 9.2. Solid Tumors

10. CD Antigen Cancer Therapy Market, by Targeted

  • 10.1. CD19
  • 10.2. CD20
  • 10.3. CD30
  • 10.4. CD33
  • 10.5. CD38
  • 10.6. CD70

11. CD Antigen Cancer Therapy Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. CD Antigen Cancer Therapy Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. CD Antigen Cancer Therapy Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States CD Antigen Cancer Therapy Market

15. China CD Antigen Cancer Therapy Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. AbbVie Inc.
  • 16.6. Alexion Pharmaceuticals, Inc.
  • 16.7. Amgen Inc.
  • 16.8. AstraZeneca PLC
  • 16.9. Bayer AG
  • 16.10. Biogen Inc.
  • 16.11. Bristol-Myers Squibb Company
  • 16.12. Celgene Corporation
  • 16.13. Eli Lilly and Company
  • 16.14. Exelixis, Inc.
  • 16.15. Genmab A/S
  • 16.16. Gilead Sciences, Inc.
  • 16.17. Illumina, Inc.
  • 16.18. Incyte Corporation
  • 16.19. Jazz Pharmaceuticals PLC
  • 16.20. Johnson & Johnson
  • 16.21. Merck & Co., Inc.
  • 16.22. Novartis AG
  • 16.23. Pfizer Inc.
  • 16.24. Regeneron Pharmaceuticals, Inc.
  • 16.25. Roche Holding AG
  • 16.26. Sanofi SA
  • 16.27. Seagen Inc.
  • 16.28. Takeda Pharmaceutical Company Limited
  • 16.29. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CD ANTIGEN CANCER THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TARGETED, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES CD ANTIGEN CANCER THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA CD ANTIGEN CANCER THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY ANTIBODY-DRUG CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY ANTIBODY-DRUG CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY ANTIBODY-DRUG CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TARGETED, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CD19, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CD19, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CD19, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CD20, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CD20, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CD20, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CD30, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CD30, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CD30, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CD33, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CD33, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CD33, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CD38, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CD38, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CD38, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CD70, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CD70, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CD70, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. AMERICAS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 40. AMERICAS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 41. AMERICAS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 42. AMERICAS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TARGETED, 2018-2032 (USD MILLION)
  • TABLE 43. NORTH AMERICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. NORTH AMERICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 45. NORTH AMERICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 46. NORTH AMERICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TARGETED, 2018-2032 (USD MILLION)
  • TABLE 47. LATIN AMERICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. LATIN AMERICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. LATIN AMERICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. LATIN AMERICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TARGETED, 2018-2032 (USD MILLION)
  • TABLE 51. EUROPE, MIDDLE EAST & AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 52. EUROPE, MIDDLE EAST & AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. EUROPE, MIDDLE EAST & AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TARGETED, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TARGETED, 2018-2032 (USD MILLION)
  • TABLE 59. MIDDLE EAST CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. MIDDLE EAST CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. MIDDLE EAST CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. MIDDLE EAST CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TARGETED, 2018-2032 (USD MILLION)
  • TABLE 63. AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. AFRICA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TARGETED, 2018-2032 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TARGETED, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. ASEAN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. ASEAN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. ASEAN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. ASEAN CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TARGETED, 2018-2032 (USD MILLION)
  • TABLE 76. GCC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GCC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. GCC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. GCC CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TARGETED, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPEAN UNION CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPEAN UNION CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPEAN UNION CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPEAN UNION CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TARGETED, 2018-2032 (USD MILLION)
  • TABLE 84. BRICS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. BRICS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. BRICS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. BRICS CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TARGETED, 2018-2032 (USD MILLION)
  • TABLE 88. G7 CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. G7 CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. G7 CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. G7 CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TARGETED, 2018-2032 (USD MILLION)
  • TABLE 92. NATO CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. NATO CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. NATO CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. NATO CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TARGETED, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CD ANTIGEN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. UNITED STATES CD ANTIGEN CANCER THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 98. UNITED STATES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. UNITED STATES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. UNITED STATES CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TARGETED, 2018-2032 (USD MILLION)
  • TABLE 101. CHINA CD ANTIGEN CANCER THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 102. CHINA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. CHINA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. CHINA CD ANTIGEN CANCER THERAPY MARKET SIZE, BY TARGETED, 2018-2032 (USD MILLION)